Doxepin Safety Profile in Elderly Female Patients with Insomnia
Common Side Effects at Low Doses (3-6 mg)
- The American Academy of Sleep Medicine recommends low-dose doxepin (3-6 mg) for elderly female patients with insomnia, as it has a remarkably benign safety profile with adverse effects comparable to placebo, showing only a mild increase in somnolence at the 6 mg dose (risk difference +0.04) and no clinically significant next-day impairment, anticholinergic effects, or withdrawal symptoms 1, 2
- Somnolence is a common side effect, with a mild increase observed primarily at 6 mg dose, with minimal impact at 3 mg 1, 3
- Headache is a reported side effect at both 3 mg and 6 mg doses, though incidence is comparable to placebo 1
- Diarrhea is noted at 3 mg dose in meta-analyses 1
- Upper respiratory infection is observed at 3 mg dose 1
Duration-Related Considerations
- The American Academy of Sleep Medicine and VA/DoD guidelines recognize that adverse event rates may increase with longer treatment duration, emphasizing use at the lowest effective dose for the shortest duration 3
Clinical Pitfalls to Avoid
- The American Academy of Sleep Medicine warns against confusing low-dose (3-6 mg) with antidepressant doses (25-300 mg), as the side effect profile is dramatically different 1